STUDY

Tazorac gel helped more people with acne than Retin-A Micro

“Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial.” Leyden JJ et al. Cutis. February 2002

Leyden JJ et al. · Cutis · February 2002

Randomized controlled trial
The finding

In a 12-week trial of 169 people with mild to moderate facial acne, 0.1% tazarotene gel led to more people reaching treatment success than 0.1% tretinoin microsponge gel (67% vs 49%). Both gels were well tolerated.

Type of study

Where this study sits on the evidence spectrum

Some kinds of studies are much more reliable than others. Studies further right do more to rule out chance and bias.

Weaker evidenceStronger evidence
Lab or animal studyCase reportCase seriesCohort studyRandomized trialMeta-analysis
Randomized and double-blind. A random process decided who got which gel, and neither the patients nor the doctors knew which one they had. That keeps expectations from skewing the results.
At a glance

Who was studied and for how long

People
169
People with acne
Length
12 weeks
Gel applied once a day
Condition
Mild to moderate inflammatory facial acne
Pimples and bumps on the face
Compared
0.1% vs 0.1%
Tazarotene gel vs tretinoin microsponge gel
How often
Once daily
Same schedule for both
Where
More than one center
Multicenter
What they did

How the study worked

169 peopleMild to moderate facial acneRANDOMSPLIT0.1%tazarotene gelOne grouponce daily0.1% tretinoinmicrosponge gelOne grouponce dailyMEASURED ATWeek 12by blinded doctors169 peopleMild to moderate facial acneRANDOMSPLIT0.1% tazarotene gelOne group · once daily0.1% tretinoinmicrosponge gelOne group · once dailyMEASURED ATWeek 12by blinded doctors
1. Split at random169 people with facial acne were randomly put in one of two groups.
2. Same routineEach group used its gel once a day for 12 weeks. Nobody knew which gel they had.
3. Several measuresDoctors counted pimples and rated overall improvement and side effects.
What they found

The results

0.1% tazarotene gel0.1% tretinoin microsponge gel

Treatment success at week 12

Success meant a clinician rated overall acne at least 50% better.

Tazarotene gel
67%
Tretinoin microsponge gel
49%
p = 0.03

Drop in noninflamed spots

Average reduction from baseline at week 12.

Tazarotene gel
60%
Tretinoin microsponge gel
38%
p = 0.02
The trial tested 0.1% tazarotene gel and a 0.1% tretinoin microsponge gel. Two patients in each group stopped because of treatment-related adverse events.
How much to trust it

Strengths and limits

Strengths

  • Randomized and double-blind, a strong design for a single study
  • Head-to-head comparison of two retinoids
  • Side effects were tracked in both groups

Limits

  • Two gels compared with each other, with no plain-gel group
  • Only mild to moderate facial acne was studied
  • Older study: 2002
  • Only 12 weeks, so long-term results are not known
Moderate confidence. A head-to-head randomized trial, but an older, mid-sized one. More trials would make this stronger.
What it means for you

The takeaway

Tazarotene did better

In this trial, 0.1% tazarotene gel gave more people treatment success than 0.1% tretinoin microsponge gel, and it cut non-inflamed lesions more.

Both gels were about equally comfortable to use. Your dermatologist can help pick the strength and form that suit your skin.

Pages that cite this study

Read more on Dermapedia

Terms in this study

Words worth knowing

Treatment success

A doctor judged the face at least 50% better overall.

Double-blind

Neither the people in the study nor the doctors measuring results knew who got which treatment.

Microsponge

A gel base that releases tretinoin slowly to reduce irritation.

Non-inflamed lesions

Blackheads and whiteheads, which are not red or swollen.

Original source

Leyden JJ, Tanghetti EA, Miller B, Ung M, Berson D, Lee J. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial.. Cutis. 2002;69(2 Suppl):12-9.

PMID 12095064